Management Co. Vii, L.L.C.P... Net Worth

The estimated Net Worth of Management Co. Vii, L.L.C.P... is at least $1.14 million dollars as of 3 November 2020. Management P owns over 250,000 units of SQZ Biotechnologies Co stock worth over $1,135,971 and over the last 4 years Management sold SQZ stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Management P SQZ stock SEC Form 4 insiders trading

Management has made over 2 trades of the SQZ Biotechnologies Co stock since 2020, according to the Form 4 filled with the SEC. Most recently Management bought 250,000 units of SQZ stock worth $4,000,000 on 3 November 2020.

The largest trade Management's ever made was buying 250,000 units of SQZ Biotechnologies Co stock on 3 November 2020 worth over $4,000,000. On average, Management trades about 240,000 units every 23 days since 2020. As of 3 November 2020 Management still owns at least 2,549,306 units of SQZ Biotechnologies Co stock.

You can see the complete history of Management P stock trades at the bottom of the page.

Insiders trading at SQZ Biotechnologies Co

Over the last 4 years, insiders at SQZ Biotechnologies Co have traded over $3,939 worth of SQZ Biotechnologies Co stock and bought 2,233,026 units worth $35,530,795 . The most active insiders traders include Holdings (Private) Ltd Temasek, Public Equities, L.P.Minne ... et Amy W Schulman. On average, SQZ Biotechnologies Co executives and independent directors trade stock every 50 days with the average trade being worth of $78,593. The most recent stock trade was executed by Richard Capasso on 15 August 2022, trading 1,183 units of SQZ stock currently worth $3,939.

What does SQZ Biotechnologies Co do?

Complete history of Management P stock trades at Metacrine et SQZ Biotechnologies Co

SQZ Biotechnologies Co executives and stock owners

SQZ Biotechnologies Co executives and other stock owners filed with the SEC include:

• Dr. Armon R. Sharei Ph.D.,
  Co-Founder, Pres, CEO, Interim Principal Financial Officer & Director
• Teri Loxam,
  Consultant & Advisor
• Dr. Howard Bernstein M.D., Ph.D.,
  Chief Scientific Officer
• Lawrence J. Knopf,
  Gen. Counsel & Sec.
• Micah Zajic,
  Chief Bus. Officer
• Ipsita Roymoulik Ph.D.,
  Sr. VP of CMC & QUALITY
• Dr. Marshelle Smith Warren M.D.,
  Chief Medical Officer
• David First,
  Chief People Officer
• Dr. Howard Bernstein,
  Chief Scientific Officer
• Richard V. Capasso CPA,
  Chief Accounting Officer
• Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD,
  Co-Founder & Member of Scientific Advisory Board
• Micah Zajic,
  Chief Financial Officer
• Howard Phd Md Bernstein,
  Interim Chief Executive Office
• Holdings (Private) Ltd Temasek,
  10% owner
• Oliver Rosen,
  Chief Medical Officer
• Paul Bolno,
  Director
• Sapna Srivastava,
  Director
• Teri Loxam,
  Chief Financial Officer
• Pushkal Garg,
  Director
• Klavs F. Jensen,
  Director
• International Group, Inc. A...,
  10% owner
• Marc Elia,
  Director
• David First,
  Chief People Officer
• Armon Sharei,
  President and CEO
• Amy W Schulman,
  Director
• Marc Schegerin,
  Director
• Lawrence J Knopf,
  General Counsel
• Eric Moessinger,
  Director
• Schulman, As Trustee The Ar...,
  10% owner
• Public Equities, L.P.Minne ...,
  
• Management Co. Vii, L.L.C.P...,
  
• Bernard Coulie,
  Director
• Patrick V.J.J. Vink,
  Director
• Richard Capasso,
  See Remarks
• Marshelle Smith Warren,
  Chief Medical Officer